{
    "clinical_study": {
        "@rank": "11678", 
        "arm_group": {
            "arm_group_label": "HAPLO", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of TBI,\n      fludarabine, cyclophosphamide and antithymocyte globulin with TCR\u03b1\u03b2-depleted graft from\n      haploidentical family donors in treating children and adolescents with malignant or\n      non-malignant diseases."
        }, 
        "brief_title": "Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Haploidentical Hematopoietic Stem Cell Transplantation", 
            "Malignant Disease", 
            "Non-malignant Disease"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        A. Disease inclusions\n\n          1. Hematologic malignancy:\n\n               -  Acute lymphoblastic leukemia including induction failure, CR1 (Ph+, t(4:11),\n                  hypodiploid and other very high risk features), \u2265 CR2, infant ALL with MLL or\n                  other unfavorable features\n\n               -  Acute myeloid leukemia excluding CR1 with t(8:21), inv(16), t(15:17), and Down\n                  syndrome\n\n               -  Myelodysplastic syndrome: RCC with -7 or RCC in need of transfusion\n\n               -  Chronic myeloid leukemia in AP\n\n               -  Juvenile myelomonocytic leukemia\n\n               -  Malignant lymphoma, NHL or HD, after failed autologous HSCT\n\n               -  Other\n\n          2. Non-hematologic malignancy\n\n               -  Relapsed or refractory solid tumors including neuroblastoma, rhabdomyosarcoma\n                  and so on\n\n          3. Non-malignant hematologic disease\n\n               -  Acquired severe and very severe aplastic anemia\n\n               -  Fanconi anemia\n\n               -  Paroxysmal nocturnal hemoglobinuria\n\n               -  Congenital dyserythropoietic anemia\n\n               -  Others\n\n          4. Inherited or metabolic disease\n\n               -  Hemophagocytic lymphohistiocytosis\n\n               -  Malignant osteopetrosis\n\n               -  Storage diseases\n\n               -  Others B. Recipient inclusions\n\n        1. Age < 21 years 2. No HLA-identical stem cell donor available 3. Lansky-Play performance\n        score >60 4. No active infection at the time of transplantation\n\n        Exclusion Criteria:\n\n          1. HIV-infection\n\n          2. Presence of active and serious infection\n\n          3. Cardiac ejection fraction <35% on echocardiography\n\n          4. Severe pulmonary dysfunction (DLCO <30%)\n\n          5. Liver function abnormalities with bilirubin >4mg/dL and elevation of transaminases >\n             400U/L\n\n          6. Concurrent severe or uncontrolled medical disease\n\n          7. Patients who are pregnant\n\n          8. Patients unwilling or unable to comply with the protocol or unable to give informed\n             consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014506", 
            "org_study_id": "AMCPHO-SCT1303"
        }, 
        "intervention": [
            {
                "arm_group_label": "HAPLO", 
                "description": "40mg/M2 once daily IV on days -7 to -2", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "50 mg/kg IV on day -3 and -2", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "Beginning on day 4 and continuing until blood counts recover", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)", 
                "intervention_name": "Total body irradiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "intervention_name": "TCR\u03b1\u03b2-depleted hematopoietic cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "Immunogenetic depletion of TCR\u03b1\u03b2 cells", 
                "intervention_name": "CliniMACS", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Lenograstim", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Children and adolescents", 
            "Malignant disease", 
            "Non-malignant disease", 
            "TCR\u03b1\u03b2 depletion", 
            "Haploidentical hematopoietic stem cell transplantation"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "link": [
            {
                "description": "Stem cell transplant", 
                "url": "http://www.mayoclinic.com/health/stem-cell-transplant/MY00089/METHOD=print"
            }, 
            {
                "description": "fludarabine", 
                "url": "http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692003.html"
            }, 
            {
                "description": "cyclophosphamide", 
                "url": "http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682080.html"
            }, 
            {
                "description": "stem cell transplantation", 
                "url": "http://www.cancer.org/acs/groups/cid/documents/webcontent/003215-pdf.pdf"
            }, 
            {
                "description": "leukemia", 
                "url": "http://www.nlm.nih.gov/medlineplus/leukemia.html"
            }
        ], 
        "location": {
            "contact": {
                "email": "hojim@amc.seoul.kr", 
                "last_name": "Ho Joon Im, MD & PhD", 
                "phone": "82-2-3010-3371"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Ho Joon Im, MD & PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "hojim@amc.seoul.kr", 
            "last_name": "Ho Joon Im, MD, PhD", 
            "phone": "82-2-3010-3371"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Ho Joon Im, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate tralsplant-related mortality after haploidentical hematopoietic stem cell transplantation using TCR\u03b1\u03b2-depleted graft", 
            "safety_issue": "Yes", 
            "time_frame": "1 year posttransplant"
        }, 
        "reference": [
            {
                "PMID": "24141651", 
                "citation": "Park JA, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ, Im HJ. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant. 2013 Oct 21. doi: 10.1038/bmt.2013.163. [Epub ahead of print]"
            }, 
            {
                "PMID": "23380343", 
                "citation": "Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Chi HS, Seo JJ. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2013 May;19(5):754-9. doi: 10.1016/j.bbmt.2013.01.023. Epub 2013 Feb 1."
            }, 
            {
                "PMID": "23993299", 
                "citation": "Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, Vogel W, Huppert V, Handgretinger R. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013 Oct;15(10):1253-8. doi: 10.1016/j.jcyt.2013.05.014."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014506"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Ho Joon Im", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess engraftment and graft failure", 
                "safety_issue": "Yes", 
                "time_frame": "28 days posttransplant"
            }, 
            {
                "measure": "To estimate the risk of acute GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "100 days posttransplant"
            }, 
            {
                "measure": "To estimate the incidence of relapse", 
                "safety_issue": "Yes", 
                "time_frame": "100 days and 1 year post-transplant"
            }, 
            {
                "measure": "To estimate the incidence and severity of chronic GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "1 year posttransplant"
            }, 
            {
                "measure": "To estimate the overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "1 year posttransplant"
            }, 
            {
                "measure": "To estimate the incidence of bacterial, fungal and viral infection", 
                "safety_issue": "Yes", 
                "time_frame": "100 days and 1 year posttransplant"
            }, 
            {
                "measure": "To estimate the reactivation rate of CMV, EBV", 
                "safety_issue": "Yes", 
                "time_frame": "100 days and 1 year posttransplant"
            }, 
            {
                "measure": "To evaluate the immune reconstitution of T, B, and NK cells", 
                "safety_issue": "No", 
                "time_frame": "days 7, 14, 21, 28, 60, 90, 180, 270, and 365 days post-transplant"
            }, 
            {
                "measure": "To evaluate the lineage-specific chimerism using flow cytomery of CD3+, CD19, CD56, TCR \u03b1\u03b2, and TCR\u03b3\u03b4 at pre-transplant", 
                "safety_issue": "No", 
                "time_frame": "days 7, 10, 14, 21, 28, 60, 90, 180, 270 and 365 post-transplant"
            }, 
            {
                "measure": "To assess event free survival", 
                "safety_issue": "Yes", 
                "time_frame": "1 year posttransplant"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}